Document Detail


Effects of somatostatin in patients with portal hypertension.
MedLine Citation:
PMID:  2900207     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Portal hypertension is a common complication of chronic liver disease. Conventional therapy consists of surgery and palliative measures for the hemodynamic problem. It has been recently reported that somatostatin may reduce portal pressure without altering the systemic circulation and so reducing hepatic blood flow. This peptide also causes a significant fall in azygos circulation in patients with esophageal varices. The mechanism of this effect is unclear although suppression of intestinal vasodilating hormones and of glucagon have been claimed to play a role. Comparative clinical studies have shown somatostatin to be superior to the standard vasopressin treatment. Recent findings suggest that the efficacy of somatostatin can be increased by administering this peptide in repeated intravenous bolus injections. New derivatives, specially long-acting peptides, may eventually prove beneficial in the chronic treatment of this complication.
Authors:
J Bosch; D Kravetz; R Mastai; M Navasa; G Silva; J Chesta; J Rodes
Related Documents :
6477827 - Clinical, pharmacological and immunological aspects of delayed pressure urticaria.
9542687 - Engineering analysis of penile hemodynamic and structural-dynamic relationships: part i...
18549907 - Warfarin-induced bleeding complications - clinical presentation and therapeutic options.
17336417 - At1 receptor antagonist candesartan in selected cirrhotic patients: effect on portal pr...
12881897 - Factors affecting the stability of the performance of ambient fine-particle concentrators.
11174737 - Monitoring of intrathecal oxygen tension during experimental aortic occlusion predicts ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hormone research     Volume:  29     ISSN:  0301-0163     ISO Abbreviation:  Horm. Res.     Publication Date:  1988  
Date Detail:
Created Date:  1988-09-16     Completed Date:  1988-09-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366126     Medline TA:  Horm Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  99-102     Citation Subset:  IM    
Affiliation:
Hepatic Haemodynamics Laboratory, Hospital Clinic i Provincial, University of Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Pressure / drug effects
Esophageal and Gastric Varices / drug therapy
Humans
Hypertension, Portal / drug therapy*,  physiopathology
Liver Cirrhosis / physiopathology
Renal Circulation / drug effects
Somatostatin / therapeutic use*
Chemical
Reg. No./Substance:
51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somato...
Next Document:  C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors.